Streamlining the dynamin epilepsy drug pipeline

简化动力癫痫药物管道

• 批准号: DP1095780
• 负责人: Prof Adam McCluskey
• 金额: $ 30.51万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-06-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP1095780
• 关键词: Streamlining; dynamin; epilepsy; drug; pipeline

Epilepsy affects up to one percent of Australia's population, yet one in three fail to respond to current medications. Our results will greatly impact on development of future epilepsy therapy. Identification of a new target for epileptic will allow better drug design to improve the potency of our lead drugs. This holds hope that new generation drugs will be more effective. The drugs are predicted to have fewer complications and side-effects. The outcome has the potential to vastly improve prospects for up to 200,000 Australians. Intellectual property (IP) retained in Australia will generate future biotechnology industry. The novel chemical biological approaches will facilitate training of future generations of Australian scientists.

癫痫症影响着多达百分之一的澳大利亚人口，但三分之一的人对当前的药物治疗无效。 我们的结果将对未来癫痫治疗的发展产生重大影响。癫痫新靶点的确定将有助于更好的药物设计，从而提高我们的先导药物的效力。 这为新一代药物更有效带来了希望。预计这些药物的并发症和副作用会更少。这一结果有可能极大改善多达 20 万澳大利亚人的前景。澳大利亚保留的知识产权（IP）将催生未来的生物技术产业。新颖的化学生物学方法将促进未来几代澳大利亚科学家的培训。